{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:17:44Z","timestamp":1789388264902,"version":"build-2803163510"},"reference-count":27,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"23","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2013,8,10]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> The phase II part of the phase I\/II GAUGUIN study evaluated the efficacy and safety of two different doses of obinutuzumab (GA101), a type II, glycoengineered, humanized anti-CD20 monoclonal antibody, in patients with relapsed\/refractory indolent non-Hodgkin lymphoma. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> Patients were randomly assigned to receive eight cycles of obinutuzumab (GA101) as a flat dose of 400 mg on days 1 and 8 of cycle 1 and also on day 1 of cycles 2 to 8 (400\/400 mg) or 1,600 mg on days 1 and 8 of cycle 1 and 800 mg on day 1 of cycles 2 to 8 (1,600\/800 mg). <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Forty patients were enrolled, including 34 with follicular lymphoma; 38 of 40 patients had previously received rituximab and 22 of 40 were rituximab refractory. The overall response rate at the end of treatment was 55% (95% CI, 32% to 76%) in the 1,600\/800-mg group (9% complete responders) and 17% (95% CI, 4% to 41%) in the 400\/400-mg group (no complete responders). Five of 10 rituximab-refractory patients had an end-of-treatment response in the 1,600\/800-mg group versus one of 12 in the 400\/400-mg group. Median progression-free survival was 11.9 months in the 1,600\/800-mg group (range, 1.8 to 33.9+ months) and 6.0 months in the 400\/400-mg group (range, 1.0 to 33.9+ months). The most common adverse events were infusion-related reactions (IRRs) seen in 73% of patients, but only two patients had grade 3 to 4 IRRs (both in the 1,600\/800-mg group). No IRRs were considered serious, and no patients withdrew for IRRs. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> The 1,600\/800-mg dose schedule of obinutuzumab (GA101) has encouraging activity with an acceptable safety profile in relapsed\/refractory indolent non-Hodgkin lymphoma. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2012.46.9718","type":"journal-article","created":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T03:19:24Z","timestamp":1373339964000},"page":"2920-2926","source":"Crossref","is-referenced-by-count":129,"title":["Obinutuzumab (GA101) in Patients With Relapsed\/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study"],"prefix":"10.1200","volume":"31","author":[{"given":"Gilles A.","family":"Salles","sequence":"first","affiliation":[{"name":"Gilles A. Salles, Hospices Civils de Lyon-Universit\u00e9 de Lyon, Pierre-B\u00e9nite; Franck Morschhauser, EA 4481 GRIIOT, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille; Philippe Solal-C\u00e9ligny, Institut de Canc\u00e9rologie de l'Ouest, Nantes; Catherine Thieblemont, H\u00f4pital Saint-Louis, Paris; Thierry Lamy, Centre Hospitalier Universitaire (CHU) de Rennes, Rennes; Herv\u00e9 Tilly, Centre Henri-Becquerel, Universit\u00e9 de Rouen, Rouen; Emmanuel Gyan, CHU de Tours, Clinical Investigation Center, Institut National..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[{"name":"Gilles A. Salles, Hospices Civils de Lyon-Universit\u00e9 de Lyon, Pierre-B\u00e9nite; Franck Morschhauser, EA 4481 GRIIOT, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille; Philippe Solal-C\u00e9ligny, Institut de Canc\u00e9rologie de l'Ouest, Nantes; Catherine Thieblemont, H\u00f4pital Saint-Louis, Paris; Thierry Lamy, Centre Hospitalier Universitaire (CHU) de Rennes, Rennes; Herv\u00e9 Tilly, Centre Henri-Becquerel, Universit\u00e9 de Rouen, Rouen; Emmanuel Gyan, CHU de Tours, Clinical Investigation Center, Institut National..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Solal-C\u00e9ligny","sequence":"additional","affiliation":[{"name":"Gilles A. Salles, Hospices Civils de Lyon-Universit\u00e9 de Lyon, Pierre-B\u00e9nite; Franck Morschhauser, EA 4481 GRIIOT, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille; Philippe Solal-C\u00e9ligny, Institut de Canc\u00e9rologie de l'Ouest, Nantes; Catherine Thieblemont, H\u00f4pital Saint-Louis, Paris; Thierry Lamy, Centre Hospitalier Universitaire (CHU) de Rennes, Rennes; Herv\u00e9 Tilly, Centre Henri-Becquerel, Universit\u00e9 de Rouen, Rouen; Emmanuel Gyan, CHU de Tours, Clinical Investigation Center, Institut National..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thieblemont","sequence":"additional","affiliation":[{"name":"Gilles A. Salles, Hospices Civils de Lyon-Universit\u00e9 de Lyon, Pierre-B\u00e9nite; Franck Morschhauser, EA 4481 GRIIOT, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille; Philippe Solal-C\u00e9ligny, Institut de Canc\u00e9rologie de l'Ouest, Nantes; Catherine Thieblemont, H\u00f4pital Saint-Louis, Paris; Thierry Lamy, Centre Hospitalier Universitaire (CHU) de Rennes, Rennes; Herv\u00e9 Tilly, Centre Henri-Becquerel, Universit\u00e9 de Rouen, Rouen; Emmanuel Gyan, CHU de Tours, Clinical Investigation Center, Institut National..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lamy","sequence":"additional","affiliation":[{"name":"Gilles A. Salles, Hospices Civils de Lyon-Universit\u00e9 de Lyon, Pierre-B\u00e9nite; Franck Morschhauser, EA 4481 GRIIOT, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille; Philippe Solal-C\u00e9ligny, Institut de Canc\u00e9rologie de l'Ouest, Nantes; Catherine Thieblemont, H\u00f4pital Saint-Louis, Paris; Thierry Lamy, Centre Hospitalier Universitaire (CHU) de Rennes, Rennes; Herv\u00e9 Tilly, Centre Henri-Becquerel, Universit\u00e9 de Rouen, Rouen; Emmanuel Gyan, CHU de Tours, Clinical Investigation Center, Institut National..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Tilly","sequence":"additional","affiliation":[{"name":"Gilles A. Salles, Hospices Civils de Lyon-Universit\u00e9 de Lyon, Pierre-B\u00e9nite; Franck Morschhauser, EA 4481 GRIIOT, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille; Philippe Solal-C\u00e9ligny, Institut de Canc\u00e9rologie de l'Ouest, Nantes; Catherine Thieblemont, H\u00f4pital Saint-Louis, Paris; Thierry Lamy, Centre Hospitalier Universitaire (CHU) de Rennes, Rennes; Herv\u00e9 Tilly, Centre Henri-Becquerel, Universit\u00e9 de Rouen, Rouen; Emmanuel Gyan, CHU de Tours, Clinical Investigation Center, Institut National..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Gyan","sequence":"additional","affiliation":[{"name":"Gilles A. Salles, Hospices Civils de Lyon-Universit\u00e9 de Lyon, Pierre-B\u00e9nite; Franck Morschhauser, EA 4481 GRIIOT, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille; Philippe Solal-C\u00e9ligny, Institut de Canc\u00e9rologie de l'Ouest, Nantes; Catherine Thieblemont, H\u00f4pital Saint-Louis, Paris; Thierry Lamy, Centre Hospitalier Universitaire (CHU) de Rennes, Rennes; Herv\u00e9 Tilly, Centre Henri-Becquerel, Universit\u00e9 de Rouen, Rouen; Emmanuel Gyan, CHU de Tours, Clinical Investigation Center, Institut National..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiyuan","family":"Lei","sequence":"additional","affiliation":[{"name":"Gilles A. Salles, Hospices Civils de Lyon-Universit\u00e9 de Lyon, Pierre-B\u00e9nite; Franck Morschhauser, EA 4481 GRIIOT, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille; Philippe Solal-C\u00e9ligny, Institut de Canc\u00e9rologie de l'Ouest, Nantes; Catherine Thieblemont, H\u00f4pital Saint-Louis, Paris; Thierry Lamy, Centre Hospitalier Universitaire (CHU) de Rennes, Rennes; Herv\u00e9 Tilly, Centre Henri-Becquerel, Universit\u00e9 de Rouen, Rouen; Emmanuel Gyan, CHU de Tours, Clinical Investigation Center, Institut National..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wenger","sequence":"additional","affiliation":[{"name":"Gilles A. Salles, Hospices Civils de Lyon-Universit\u00e9 de Lyon, Pierre-B\u00e9nite; Franck Morschhauser, EA 4481 GRIIOT, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille; Philippe Solal-C\u00e9ligny, Institut de Canc\u00e9rologie de l'Ouest, Nantes; Catherine Thieblemont, H\u00f4pital Saint-Louis, Paris; Thierry Lamy, Centre Hospitalier Universitaire (CHU) de Rennes, Rennes; Herv\u00e9 Tilly, Centre Henri-Becquerel, Universit\u00e9 de Rouen, Rouen; Emmanuel Gyan, CHU de Tours, Clinical Investigation Center, Institut National..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Wassner-Fritsch","sequence":"additional","affiliation":[{"name":"Gilles A. Salles, Hospices Civils de Lyon-Universit\u00e9 de Lyon, Pierre-B\u00e9nite; Franck Morschhauser, EA 4481 GRIIOT, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille; Philippe Solal-C\u00e9ligny, Institut de Canc\u00e9rologie de l'Ouest, Nantes; Catherine Thieblemont, H\u00f4pital Saint-Louis, Paris; Thierry Lamy, Centre Hospitalier Universitaire (CHU) de Rennes, Rennes; Herv\u00e9 Tilly, Centre Henri-Becquerel, Universit\u00e9 de Rouen, Rouen; Emmanuel Gyan, CHU de Tours, Clinical Investigation Center, Institut National..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Cartron","sequence":"additional","affiliation":[{"name":"Gilles A. Salles, Hospices Civils de Lyon-Universit\u00e9 de Lyon, Pierre-B\u00e9nite; Franck Morschhauser, EA 4481 GRIIOT, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille; Philippe Solal-C\u00e9ligny, Institut de Canc\u00e9rologie de l'Ouest, Nantes; Catherine Thieblemont, H\u00f4pital Saint-Louis, Paris; Thierry Lamy, Centre Hospitalier Universitaire (CHU) de Rennes, Rennes; Herv\u00e9 Tilly, Centre Henri-Becquerel, Universit\u00e9 de Rouen, Rouen; Emmanuel Gyan, CHU de Tours, Clinical Investigation Center, Institut National..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.5376"},{"key":"B3","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann W","year":"2005","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153189"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.4556"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.5827"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2007.06.151"},{"key":"B10","first-page":"5480","volume":"63","author":"Chan HT","year":"2003","journal-title":"Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2031"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-296913"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.9117"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq027"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-117671"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-06-225979"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V116.21.3925.3925"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408773"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-404368"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3135"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70150-4"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-378323"},{"key":"B24","volume":"96","author":"Morschhauser F","year":"2011","journal-title":"Haematologica"},{"key":"B25","volume":"96","author":"Cartron GC","year":"2011","journal-title":"Haematologica"},{"key":"B26","doi-asserted-by":"crossref","first-page":"iv131","DOI":"10.1093\/annonc\/mdr209","volume":"22","author":"Cartron G","year":"2011","journal-title":"Ann Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.270.270"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2012.46.9718","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T22:51:05Z","timestamp":1653519065000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2012.46.9718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,10]]},"references-count":27,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2013,8,10]]}},"alternative-id":["10.1200\/JCO.2012.46.9718"],"URL":"https:\/\/doi.org\/10.1200\/jco.2012.46.9718","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,10]]}}}